##### Table of Contents

---

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549



---



FORM 10-Q



---



|x | QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
|- | ---------------------------------------------------------------------------------------



FOR THE QUARTERLY PERIOD ENDED JUNE 30, 2005



OR



| ̈ | TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
|- | ----------------------------------------------------------------------------------------



FOR THE TRANSITION PERIOD FROM  TO
.



COMMISSION FILE NO. 000-31519



---



CURON MEDICAL, INC.

(Exact name of registrant as specified in its charter)



---



|                                                               |  |                                     
|-------------------------------------------------------------- |  | ------------------------------------
|Delaware                                                       |  | 77-0470324                          
|(State or other jurisdiction of incorporation or organization) |  | (I.R.S. Employer Identification No.)



46117 Landing
Parkway

Fremont, CA 94538

(Address of principal executive offices, including zip code)



(510) 661-1800

(Registrants telephone number, including area code)



---



Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934
during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports) and (2) has been subject to such filing requirements for the past 90 days.    Yes  x    No ̈



Indicate by check mark whether the registrant is an accelerated filer (as defined in Rule 12b-2 of the Exchange
Act).    Yes ̈No  x



As of July 27, 2005, 43,349,465 shares of the Registrants Common Stock
were outstanding.



---



---

##### Table of Contents

CURON MEDICAL, INC.

INDEX



|           |  |                       |  |                                                                                                                  |  |   
|---------- |  | --------------------- |  | ---------------------------------------------------------------------------------------------------------------- |  | --
|           |  |                       |  | Page                                                                                                            
|PART I.    |  | FINANCIAL INFORMATION |  | 3                                                                                                               
|           |  |                       | 
|           |  | Item 1.               |  | Financial Statements (unaudited)                                                                                 |  | 3 
|           |  |                       | 
|           |  |                       |  | Condensed Consolidated Balance Sheets as of June 30, 2005 and December 31, 2004                                  |  | 3 
|           |  |                       | 
|           |  |                       |  | Condensed Consolidated Statements of Operations for the three and six month periods ended June 30, 2005 and 2004 |  | 4 
|           |  |                       | 
|           |  |                       |  | Condensed Consolidated Statements of Cash Flows for the six month periods ended June 30, 2005 and 2004           |  | 5 
|           |  |                       | 
|           |  |                       |  | Notes to Condensed Consolidated Financial Statements                                                             |  | 6 
|           |  |                       | 
|           |  | Item 2.               |  | Managements Discussion and Analysis of Financial Condition and Results of Operations                            |  | 10
|           |  |                       | 
|           |  | Item 3.               |  | Quantitative and Qualitative Disclosures of Market Risk                                                          |  | 21
|           |  |                       | 
|           |  | Item 4.               |  | Controls and Procedures                                                                                          |  | 21
|           |  |                      
|PART II.   |  | OTHER INFORMATION     |  | 22                                                                                                              
|           |  |                       | 
|           |  | Item 1.               |  | Legal Proceedings                                                                                                |  | 22
|           |  |                       | 
|           |  | Item 2.               |  | Unregistered Sale of Equity Securities and Use of Proceeds                                                       |  | 22
|           |  |                       | 
|           |  | Item 3.               |  | Defaults Upon Senior Securities                                                                                  |  | 22
|           |  |                       | 
|           |  | Item 4.               |  | Submission of Matters to a Vote of Security Holders                                                              |  | 22
|           |  |                       | 
|           |  | Item 5.               |  | Other Information                                                                                                |  | 23
|           |  |                       | 
|           |  | Item 6.               |  | Exhibits                                                                                                         |  | 23
|           | 
|SIGNATURES |  | 24                   



2



---

##### Table of Contents

PART I FINANCIAL INFORMATION



Item 1. Financial Statements



CURON MEDICAL, INC.

Condensed Consolidated Balance Sheets

(Unaudited, in thousands)



|                                           |  |              |          |   |                  |   |         |  
|------------------------------------------ |  | ------------ | -------- | - | ---------------- | - | ------- | -
|                                           |  | June 30,2005 |          |   | December 31,2004 |  
|Assets                                     |  |              |          |   |                  |   |         |  
|Current assets:                            |  |              |          |   |                  |   |         |  
|Cash and cash equivalents                  |  | $            | 7,802    |   |                  | $ | 374     |  
|Marketable securities                      |  |              | 2,105    |   |                  |   | 5,518   |  
|Accounts receivable, net                   |  |              | 741      |   |                  |   | 620     |  
|Inventories, net                           |  |              | 1,011    |   |                  |   | 777     |  
|Prepaid expenses and other current assets  |  |              | 1,107    |   |                  |   | 987     |  
|                                           |  |              |          |   |                  |   |         |  
|Total current assets                       |  |              | 12,766   |   |                  |   | 8,276   |  
|                                           |  |             
|Property and equipment, net                |  |              | 454      |   |                  |   | 551     |  
|Other assets                               |  |              | 325      |   |                  |   | 330     |  
|                                           |  |              |          |   |                  |   |         |  
|Total assets                               |  | $            | 13,545   |   |                  | $ | 9,157   |  
|                                           |  |              |          |   |                  |   |         |  
|Liabilities and Stockholders Equity       |  |              |          |   |                  |   |         |  
|Current liabilities:                       |  |              |          |   |                  |   |         |  
|Accounts payable                           |  | $            | 531      |   |                  | $ | 473     |  
|Accrued liabilities                        |  |              | 1,236    |   |                  |   | 1,121   |  
|Notes payable                              |  |              | 444      |   |                  |   | 57      |  
|                                           |  |              |          |   |                  |   |         |  
|Total current liabilities                  |  |              | 2,211    |   |                  |   | 1,651   |  
|                                           |  |             
|Warrant obligation                         |  |              | 4,733    |   |                  |   | 469     |  
|Other                                      |  |              | 101      |   |                  |   | 124     |  
|                                           |  |              |          |   |                  |   |         |  
|Total liabilities                          |  |              | 7,045    |   |                  |   | 2,244   |  
|                                           |  |              |          |   |                  |   |         |  
|Contingencies and commitments (Note 5)     |  |              |          |   |                  |   |         |  
|                                           |  |             
|Stockholders equity:                      |  |              |          |   |                  |   |         |  
|Common stock                               |  |              | 43       |   |                  |   | 25      |  
|Additional paid-in capital                 |  |              | 108,013  |   |                  |   | 101,739 |  
|Accumulated deficit                        |  |              | (101,319 | ) |                  |   | (94,607 | )
|Treasury stock                             |  |              | (234     | ) |                  |   | (234    | )
|Accumulated other comprehensive loss       |  |              | (3       | ) |                  |   | (10     | )
|                                           |  |              |          |   |                  |   |         |  
|Total stockholders equity                 |  |              | 6,500    |   |                  |   | 6,913   |  
|                                           |  |              |          |   |                  |   |         |  
|Total liabilities and stockholders equity |  | $            | 13,545   |   |                  | $ | 9,157   |  
|                                           |  |              |          |   |                  |   |         |  



See accompanying notes
to condensed consolidated financial statements



3



---

##### Table of Contents

CURON MEDICAL, INC.

Condensed Consolidated Statements of Operations

(Unaudited)

(in thousands, except per share
amounts)



|                                                               |  |                                     |        |   |                                   |   |        |      |  |   |        |   |  |   |        |  
|-------------------------------------------------------------- |  | ----------------------------------- | ------ | - | --------------------------------- | - | ------ | ---- |  | - | ------ | - |  | - | ------ | -
|                                                               |  | For the Three Months Ended June 30, |        |   | For the Six Months Ended June 30, |  
|                                                               |  | 2005                                |        |   | 2004                              |   |        | 2005 |  |   | 2004   |  
|Revenues                                                       |  | $                                   | 1,152  |   |                                   | $ | 931    |      |  | $ | 2,009  |   |  | $ | 1,837  |  
|Cost of goods sold                                             |  |                                     | 1,013  |   |                                   |   | 1,110  |      |  |   | 1,995  |   |  |   | 2,132  |  
|                                                               |  |                                     |        |   |                                   |   |        |      |  |   |        |   |  |   |        |  
|Gross income (loss)                                            |  |                                     | 139    |   |                                   |   | (179   | )    |  |   | 14     |   |  |   | (295   | )
|                                                               |  |                                     |        |   |                                   |   |        |      |  |   |        |   |  |   |        |  
|Operating expenses:                                            |  |                                     |        |   |                                   |   |        |      |  |   |        |   |  |   |        |  
|Research and development                                       |  |                                     | 301    |   |                                   |   | 433    |      |  |   | 594    |   |  |   | 930    |  
|Clinical and regulatory                                        |  |                                     | 320    |   |                                   |   | 282    |      |  |   | 520    |   |  |   | 635    |  
|Sales and marketing                                            |  |                                     | 2,509  |   |                                   |   | 2,009  |      |  |   | 4,294  |   |  |   | 4,078  |  
|General and administrative                                     |  |                                     | 929    |   |                                   |   | 1,028  |      |  |   | 1,868  |   |  |   | 2,013  |  
|                                                               |  |                                     |        |   |                                   |   |        |      |  |   |        |   |  |   |        |  
|Total operating expenses                                       |  |                                     | 4,059  |   |                                   |   | 3,752  |      |  |   | 7,276  |   |  |   | 7,656  |  
|                                                               |  |                                     |        |   |                                   |   |        |      |  |   |        |   |  |   |        |  
|Operating loss                                                 |  |                                     | (3,920 | ) |                                   |   | (3,931 | )    |  |   | (7,262 | ) |  |   | (7,951 | )
|                                                               |  |                                     |        |  
|Interest income                                                |  |                                     | 32     |   |                                   |   | 42     |      |  |   | 49     |   |  |   | 81     |  
|Decrease in warrant obligation                                 |  |                                     | 153    |   |                                   |   | 679    |      |  |   | 491    |   |  |   | 1,122  |  
|Other expense, net                                             |  |                                     | (11    | ) |                                   |   | (1     | )    |  |   | 10     |   |  |   | (15    | )
|                                                               |  |                                     |        |   |                                   |   |        |      |  |   |        |   |  |   |        |  
|Net loss                                                       |  | $                                   | (3,746 | ) |                                   | $ | (3,211 | )    |  | $ | (6,712 | ) |  | $ | (6,763 | )
|                                                               |  |                                     |        |   |                                   |   |        |      |  |   |        |   |  |   |        |  
|Net loss per share, basic and diluted                          |  | $                                   | (0.11  | ) |                                   | $ | (0.13  | )    |  | $ | (0.23  | ) |  | $ | (0.29  | )
|                                                               |  |                                     |        |   |                                   |   |        |      |  |   |        |   |  |   |        |  
|Shares used in computing net loss per share, basic and diluted |  |                                     | 33,668 |   |                                   |   | 24,385 |      |  |   | 29,263 |   |  |   | 23,522 |  
|                                                               |  |                                     |        |   |                                   |   |        |      |  |   |        |   |  |   |        |  



See accompanying notes
to condensed consolidated financial statements



4



---

##### Table of Contents

CURON MEDICAL, INC.

Condensed Consolidated Statements of Cash Flows

(Unaudited, in thousands)



|                                                                            |  |                                    |        |   |      |   |         |  
|--------------------------------------------------------------------------- |  | ---------------------------------- | ------ | - | ---- | - | ------- | -
|                                                                            |  | For the Six Months Ended, June 30, |       
|                                                                            |  | 2005                               |        |   | 2004 |  
|Cash Flows From Operating Activities                                        |  |                                    |        |   |      |   |         |  
|Net loss                                                                    |  | $                                  | (6,712 | ) |      | $ | (6,763  | )
|Adjustments to reconcile net loss to net cash used in operating activities: |  |                                    |        |   |      |   |         |  
|Depreciation and amortization                                               |  |                                    | 148    |   |      |   | 246     |  
|Stock-based compensation                                                    |  |                                    | (16    | ) |      |   | 4       |  
|Loss on disposal of fixed assets                                            |  |                                    |       |   |      |   | 11      |  
|Decrease in warrant obligation                                              |  |                                    | (491   | ) |      |   | (1,122  | )
|Amortization of premium on securities                                       |  |                                    | 28     |   |      |   | 276     |  
|Changes in assets and liabilities:                                          |  |                                    |        |   |      |   |         |  
|Accounts receivable, net                                                    |  |                                    | (121   | ) |      |   | 254     |  
|Inventories, net                                                            |  |                                    | (234   | ) |      |   | (217    | )
|Prepaid expenses and other current assets                                   |  |                                    | (120   | ) |      |   | (371    | )
|Other assets                                                                |  |                                    | 5      |   |      |   |        |  
|Accounts payable                                                            |  |                                    | 58     |   |      |   | (114    | )
|Accrued liabilities                                                         |  |                                    | 115    |   |      |   | 174     |  
|Decrease in settlement of legal liabilities                                 |  |                                    |       |   |      |   | (1,250  | )
|Other long-term assets and liabilities                                      |  |                                    | (23    | ) |      |   | 44      |  
|                                                                            |  |                                    |        |   |      |   |         |  
|Net cash used in operating activities                                       |  |                                    | (7,363 | ) |      |   | (8,828  | )
|                                                                            |  |                                    |        |   |      |   |         |  
|Cash Flows From Investing Activities                                        |  |                                    |        |   |      |   |         |  
|Purchase of property and equipment                                          |  |                                    | (51    | ) |      |   | (378    | )
|Purchase of marketable securities                                           |  |                                    | (2,108 | ) |      |   | (11,960 | )
|Proceeds from maturities of marketable securities                           |  |                                    | 5,500  |   |      |   | 4,850   |  
|                                                                            |  |                                    |        |   |      |   |         |  
|Net cash provided by (used in) investing activities                         |  |                                    | 3,341  |   |      |   | (7,488  | )
|                                                                            |  |                                    |        |   |      |   |         |  
|Cash Flows From Financing Activities                                        |  |                                    |        |   |      |   |         |  
|Proceeds from issuance of common stock and warrants, net of issuance costs  |  |                                    | 10,981 |   |      |   | 12,658  |  
|Exercise of stock options and ESPP                                          |  |                                    | 82     |   |      |   | 223     |  
|Proceeds from issuance of notes payable                                     |  |                                    | 675    |   |      |   | 649     |  
|Principal payments on notes payable                                         |  |                                    | (288   | ) |      |   | (251    | )
|                                                                            |  |                                    |        |   |      |   |         |  
|Net cash provided by financing activities                                   |  |                                    | 11,450 |   |      |   | 13,279  |  
|                                                                            |  |                                    |        |   |      |   |         |  
|Net increase (decrease) in cash and cash equivalents                        |  |                                    | 7,428  |   |      |   | (3,037  | )
|Cash and cash equivalents at beginning of period                            |  |                                    | 374    |   |      |   | 4,865   |  
|                                                                            |  |                                    |        |   |      |   |         |  
|Cash and cash equivalents at end of period                                  |  | $                                  | 7,802  |   |      | $ | 1,828   |  
|                                                                            |  |                                    |        |   |      |   |         |  



See accompanying notes
to the condensed consolidated financial statements



5



---

##### Table of Contents

CURON MEDICAL, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited, tabular amounts in thousands, except per share amounts)



NOTE 1. The Company and Summary of Significant Accounting Policies



The Company



Curon Medical, Inc. (the Company) was incorporated in the State of Delaware in May 1997 as Conway-Stuart Medical Inc. and changed its name to Curon Medical
Inc., in March 2000. The Company develops, manufactures and markets proprietary products for the treatment of gastrointestinal disorders.



The Company has sustained operating losses and negative cash flows from operations and expects such losses to continue in the foreseeable future. The Company has been
financing its operations primarily through its cash and cash equivalents, revenues, marketable securities, and financing activities. The Company intends to finance its operations primarily through its cash and cash equivalents, marketable
securities, future financing and future revenues. Based on its current expectations of sales and operating costs, existing capital resources will not enable the Company to maintain current and planned operations beyond the second quarter of 2006.
However, if the Company does not receive certain expected product sales, its cash balance may not sustain planned operations beyond the end of the first quarter of 2006. The Company is pursuing a number of alternatives to maximize stockholder value,
including strategic transactions, collaborative partnerships and the licensing or sale of certain of its intellectual property. Licensing or collaborative arrangements, if necessary to raise additional funds, may require the Company to relinquish
rights to certain or all of its products or technologies. If these efforts are not successful, the Company will need to raise additional capital before the end of first quarter 2006 in order to continue its operations. Any additional financing may
not be available in amounts or on terms acceptable to the Company, if at all. These issues raise substantial doubt about the Companys ability to continue as a going concern.



The accompanying condensed consolidated financial statements have been prepared on a going concern basis which contemplates continuity of
operations, realization of assets, and liquidation of liabilities in the ordinary course of business, and do not reflect adjustments that might result if the Company were not to continue as a going concern.



Basis of Presentation



The condensed consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries after elimination of
all intercompany balances and transactions. The Company operates in one reportable segment.



The accompanying unaudited condensed consolidated financial statements have been prepared by the Company in accordance with accounting principles generally accepted in the United States of America for interim
financial information and pursuant to the instructions to Form 10-Q and Article 10 of Regulation S-X promulgated by the Securities and Exchange Commission (SEC). Accordingly, they do not include all of the information and footnotes
required by generally accepted accounting principles for complete financial statements. The unaudited interim condensed consolidated financial statements have been prepared on the same basis as the annual consolidated financial statements and, in
the opinion of management, contain all adjustments (all of which are normal and recurring in nature) necessary to state fairly the financial position, results of operations and cash flows of the Company for the periods indicated. Interim results of
operations are not necessarily indicative of the results to be expected for the full year or any other interim periods.



These condensed consolidated financial statements should be read in conjunction with the audited financial statements included in the Annual Report on Form 10-K for the
year ended December 31, 2004, as filed with the SEC.



6



---

##### Table of Contents

Net Loss Per Share



Basic and diluted net loss per share is calculated as follows:



|                                     |  |                             |        |   |                           |   |        |      |  |   |        |   |  |   |        |  
|------------------------------------ |  | --------------------------- | ------ | - | ------------------------- | - | ------ | ---- |  | - | ------ | - |  | - | ------ | -
|                                     |  | Three Months Ended June 30, |        |   | Six Months Ended June 30, |  
|                                     |  | 2005                        |        |   | 2004                      |   |        | 2005 |  |   | 2004   |  
|Net loss (numerator):                |  |                             |        |   |                           |   |        |      |  |   |        |   |  |   |        |  
|Net loss                             |  | $                           | (3,746 | ) |                           | $ | (3,211 | )    |  | $ | (6,712 | ) |  | $ | (6,763 | )
|                                     |  |                             |        |   |                           |   |        |      |  |   |        |   |  |   |        |  
|Shares (denominator):                |  |                             |        |   |                           |   |        |      |  |   |        |   |  |   |        |  
|Weighted average shares outstanding  |  |                             | 33,668 |   |                           |   | 24,385 |      |  |   | 29,263 |   |  |   | 23,522 |  
|                                     |  |                             |        |   |                           |   |        |      |  |   |        |   |  |   |        |  
|Net loss per share-basic and diluted |  | $                           | (0.11  | ) |                           | $ | (0.13  | )    |  | $ | (0.23  | ) |  | $ | (0.29  | )
|                                     |  |                             |        |   |                           |   |        |      |  |   |        |   |  |   |        |  



The following shares issuable through
the Companys Employee Stock Purchase Plan (ESPP), outstanding options, and warrants were excluded from the computation of diluted net loss per share as they all had an anti-dilutive effect:



|                                               |  |          |  |      
|---------------------------------------------- |  | -------- |  | -----
|                                               |  | June 30,
|                                               |  | 2005     |  | 2004 
|Shares issuable through ESPP                   |  | 20       |  | 38   
|Shares issuable upon exercise of stock options |  | 4,485    |  | 3,618
|Shares issuable upon exercise of warrants      |  | 11,453   |  | 1,475
|                                               |  |          |  |      
|Total                                          |  | 15,958   |  | 5,131
|                                               |  |          |  |      



7



---

##### Table of Contents

Stock-Based Compensation



The Company accounts for stock-based employee compensation arrangements in accordance with provisions of Accounting Principles Board Opinion, APB, No. 25,
Accounting for Stock Issued to Employees and complies with the disclosure provisions of Statement of Financial Accounting Standards, SFAS, No. 123, Accounting for Stock-Based Compensation, as amended by SFAS No. 148,
Accounting for Stock-Based Compensation, Transition and Disclosure. Under APB No. 25, unearned stock compensation is based on the difference, if any, on the date of grant, between the fair value of the Companys common stock and the
exercise price. Had the Company determined its stock-based compensation based on the fair value at the grant dates for the awards under a method prescribed by SFAS No. 123, the Companys net loss would have been increased to the FAS 123
adjusted amounts indicated below, as amended by SFAS No. 148:



|                                                                                                         |  |                             |        |   |                           |   |        |      |  |   |        |   |  |   |        |  
|-------------------------------------------------------------------------------------------------------- |  | --------------------------- | ------ | - | ------------------------- | - | ------ | ---- |  | - | ------ | - |  | - | ------ | -
|                                                                                                         |  | Three Months Ended June 30, |        |   | Six Months Ended June 30, |  
|                                                                                                         |  | 2005                        |        |   | 2004                      |   |        | 2005 |  |   | 2004   |  
|Net loss, as reported                                                                                    |  | $                           | (3,746 | ) |                           | $ | (3,211 | )    |  | $ | (6,712 | ) |  | $ | (6,763 | )
|Add: Stock-based employee compensation expense in reported net income                                    |  |                             |       |   |                           |   |       |      |  |   |       |   |  |   | 4      |  
|Deduct: Total stock-based employee compensation expense determined under fair value based for all awards |  |                             | (225   | ) |                           |   | (176   | )    |  |   | (411   | ) |  |   | (322   | )
|                                                                                                         |  |                             |        |   |                           |   |        |      |  |   |        |   |  |   |        |  
|Net loss - FAS 123 adjusted                                                                              |  | $                           | (3,971 | ) |                           | $ | (3,387 | )    |  | $ | (7,123 | ) |  | $ | (7,081 | )
|                                                                                                         |  |                             |        |   |                           |   |        |      |  |   |        |   |  |   |        |  
|Net loss per share - as reported Basic and diluted                                                       |  | $                           | (0.11  | ) |                           | $ | (0.13  | )    |  | $ | (0.23  | ) |  | $ | (0.29  | )
|                                                                                                         |  |                             |        |   |                           |   |        |      |  |   |        |   |  |   |        |  
|Net loss per share - FAS 123 adjusted Basic and diluted                                                  |  | $                           | (0.12  | ) |                           | $ | (0.14  | )    |  | $ | (0.24  | ) |  | $ | (0.30  | )
|                                                                                                         |  |                             |        |   |                           |   |        |      |  |   |        |   |  |   |        |  



The Company accounts for equity
instruments issued to non-employees in accordance with the provisions of SFAS No. 123 and Emerging Issues Task Force No. 96-18, Accounting for Equity Instruments That Are Issued to Other Than Employees for Acquiring, or in Conjunction with
Selling, Goods or Services. The equity instruments are valued using the Black-Scholes model. All unvested shares are marked to market until such options vest.



Product Warranty



The Company generally warrants its capital equipment products against defects for a period of one year and records a liability for such product warranty obligations at
the time of sale based upon historical experience. The Company also sells separately priced extended warranties to provide additional warranty coverage and recognizes the related revenue on a straight-line basis over the extended warranty period,
which is generally one to four years. Costs associated with services performed under the extended warranty obligation are expensed as incurred.



8



---

##### Table of Contents

Changes in product warranty obligations, including separately priced extended warranty obligations, for the six months
ended June 30, 2005 and 2004 are as follows:



|                                                                                                |  |                                   |      |    |      |   |      |   
|----------------------------------------------------------------------------------------------- |  | --------------------------------- | ---- | -- | ---- | - | ---- | --
|                                                                                                |  | For the Six Months Ended June 30, |     
|                                                                                                |  | 2005                              |      |    | 2004 |  
|Balance as of the beginning of the period                                                       |  | $                                 | 83   |    |      | $ | 58   |   
|Add: Accruals for warranties issued                                                             |  |                                   | 14   |    |      |   | 28   |   
|Less: Settlements made Revenue recognized under separately priced extended warranty obligations |  |                                   | (5(4 | )) |      |   | (1(6 | ))
|                                                                                                |  |                                   |      |    |      |   |      |   
|Balance as of the end of the period                                                             |  | $                                 | 88   |    |      | $ | 79   |   
|                                                                                                |  |                                   |      |    |      |   |      |   



NOTE 2. Issuance of Common Stock
and Warrants



On April 8 and June 3, 2005, the Company completed the
private placement of common stock and warrants with a group of institutional investors and raised approximately $12.0 million in gross proceeds. Net proceeds after offering costs and expenses were approximately $11million. The Company paid to the
parties that acted as its agents in connection with this private placement fees of $859,000 in cash and issued warrants to purchase 553,352 shares of its common stock as additional consideration. The terms of these warrants are identical to those
issued to the investors. The transaction was completed in two closings, and involved the sale of an aggregate of 18,445,078 newly issued shares of the Companys common stock at a price of $0.65 per share and warrants to purchase an aggregate of
9,222,539 shares of common stock with an exercise price of $1.00 per share. In the first closing, the Company issued 4,962,614 shares of common stock and warrants to purchase 2,481,298 shares of common stock, for gross proceeds to the Company of
approximately $3.2 million. The aggregate fair value of the warrants on the date of issuance was approximately $1.4 million. In the second closing, the Company issued 13,482,464 shares of common stock and warrants to purchase 6,741,241 shares of
common stock, for gross proceeds to the Company of approximately $8.8 million. The aggregate fair value of the warrants on the date of issuance was approximately $3.3 million. The common stock warrants have a five-year term and become exercisable on
October 8, 2005 and December 3, 2005, respectively. In addition, as detailed in the common stock purchase warrant agreement, the warrants include a provision whereby the Company could be required to repurchase these warrants upon the occurrence of
certain Fundamental Transactions defined in the agreement. If the Fundamental Transaction is consummated by the Company after the second anniversary of the issuance of the warrants and the consideration received by the warrant holder is
less than 30% in excess of the warrants exercise price, the Company (or the Companys successor) must purchase the warrant from a holder. The purchase price of the warrant will be equal to the Black-Scholes value of the unexercised
portion of the warrant as of the date the request to purchase is made. As a result, the aggregate fair value of the warrants of $1.4 and $3.3 million was recorded as a liability with the remaining net proceeds of $6.3 million recorded as equity in
the accompanying condensed consolidated balance sheet. The warrants were valued on April 8, and June 3, 2005 using the Black-Scholes model with the following assumptions: 5 year expected life, risk free interest rate of 4.08% and 3.72%,
respectively, dividend yield of zero and a volatility of 100%.



In accordance
with the warrant purchase agreement and following the first closing of financing, the Company notified holders of common stock warrants issued in February 2004 that the exercise price of the warrants decreased from $4.71 to $3.85 and the number of
common stock shares to purchase upon exercise of warrants increased from 905,625 to 1,107,920, so that the aggregate exercise price of $4,265,494 remains unchanged.



9



---

##### Table of Contents

NOTE 3. Inventories



|                |  |          |       |              |   |    
|--------------- |  | -------- | ----- | ------------ | - | ---
|                |  | June 30, |       | December 31,
|                |  | 2005     |       | 2004        
|Inventories:    |  |          |       |              |   |    
|Raw materials   |  | $        | 564   |              | $ | 563
|Work-in-process |  |          | 89    |              |   | 13 
|Finished goods  |  |          | 358   |              |   | 201
|                |  |          |       |              |   |    
|                |  | $        | 1,011 |              | $ | 777
|                |  |          |       |              |   |    



NOTE 4. Non-Employee Stock
Compensation



Stock-based compensation (benefit) expense included in the
Condensed Consolidated Statements of Operations is as follows:



|                         |  |                             |    |   |                          |   |     |      |  |   |      |   |  |   |  
|------------------------ |  | --------------------------- | -- | - | ------------------------ | - | --- | ---- |  | - | ---- | - |  | - | -
|                         |  | Three Months Ended June 30, |    |   | Six Months Ended June 30
|                         |  | 2005                        |    |   | 2004                     |   |     | 2005 |  |   | 2004
|Research and development |  | $                           |   |   |                          | $ |    |      |  | $ |     |   |  | $ | 1
|Clinical and regulatory  |  |                             | (4 | ) |                          |   | (25 | )    |  |   | (13  | ) |  |   | 1
|Sales and marketing      |  |                             | (1 | ) |                          |   | (2  | )    |  |   | (3   | ) |  |   | 2
|                         |  |                             |    |   |                          |   |     |      |  |   |      |   |  |   |  
|                         |  | $                           | (5 | ) |                          | $ | (27 | )    |  | $ | (16  | ) |  | $ | 4
|                         |  |                             |    |   |                          |   |     |      |  |   |      |   |  |   |  



NOTE 5. Contingencies



The Company is involved in routine legal and administrative proceedings
that arise from the normal conduct of business. Management believes that the ultimate disposition of these matters will not have a material adverse effect on the financial results or condition of the Company.



In April 2003, a civil action was filed against the Company in United States District Court
for the Northern District of California by Federal Insurance Corporation, the Companys insurance carrier, for rescission, reformation, and restitution in connection with the Companys liability insurance policy. This policy covers, among
other things, product liability claims made against the Company by people treated with the Companys product. In October 2004, the plaintiffs summary judgment motion was granted. The Company has decided not to appeal the result of the
summary judgment and has agreed to settlement terms with Federal Insurance Corporation. The settlement as agreed will end any further liability in this matter for the Company and will result in a partial recovery of premiums paid. The Company
expects to sign the settlement documents in the third quarter of 2005.



Item 2. Managements Discussion and Analysis of Financial Condition and Results of Operations



The following discussion should be read in conjunction with the attached financial statements and notes thereto, and with our annual financial statements and notes
thereto for the fiscal year ended December 31, 2004.



This quarterly report,
including the following sections, contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements include statements relating to our expectations as to the rates of market adoption of
our products, the timing and effect on market adoption of reimbursement approvals, the timing and extent of technical improvements to our products, and our ability to achieve higher sales volume for this fiscal year. These forward-looking statements
involve risks and uncertainties. The cautionary statements set forth below and those contained in Factors That May Affect Future Results, commencing on page 15, identify important factors that could cause actual results to differ
materially from those predicted in any such forward-looking statements.



Overview



We were incorporated in Delaware in May 1997 as
Conway-Stuart Medical Inc. and changed our name to Curon Medical Inc., in March 2000. We develop, manufacture and market innovative proprietary products for the treatment of gastrointestinal disorders. Our products consist of radiofrequency
generators and single-use disposable devices.



Our first product, the
Stretta® System, received United States Food and
Drug Administration FDA, clearance in April 2000 for the



10



---

##### Table of Contents

treatment of gastroesophageal reflux disease, or GERD, which affects approximately 19 million U.S. adults on a daily basis. In patients with GERD, stomach
contents reflux backward from the stomach into the esophagus, causing a wide range of symptoms and complications, including, most commonly, persistent heartburn and chest pain. Unlike medication, which addresses GERD symptoms, our Stretta System
applies radiofrequency energy to treat the causes of GERD. The Stretta System consists of a disposable catheter with needle electrodes and our control module, which is a radiofrequency energy generator. Using the Stretta System, the physician
delivers temperature-controlled radiofrequency energy to the muscle of the lower esophageal sphincter and upper portion of the stomach. The delivery of this energy creates heat, causing tissue contraction and creating thermal lesions that resorb
over time, resulting in improved sphincter function. Clinical studies show a significant reduction in GERD symptom scores, esophageal acid exposure, and use of anti-secretory medications.



We commercially launched the Stretta System in May 2000. As of June 30, 2005, we have sold over 300 control modules and approximately 8,000
patients have been treated with the Stretta Procedure.



Our second product, the
Secca® System, is a radiofrequency energy-based system for the treatment of bowel incontinence (referred to as Fecal incontinence). Bowel incontinence is
caused by damage to the anal sphincter due to childbirth, surgery, neurological disease, injury or age, and affects up to 16 million adults in the United States. Using the Secca System, physicians deliver radiofrequency energy to the anal sphincter
muscle in the anal canal. Clinical studies have shown a reduction in bowel incontinence symptoms and improvement in general quality of life. In March 2002, we received 510(k) clearance from the FDA to market the Secca System for the treatment of
fecal incontinence in patients who have failed more conservative therapies such as diet modification and biofeedback. We undertook a limited test launch of Secca in June 2002, and fully launched the product commercially in May 2003.



We have a direct sales force to market and sell our products in the United States. We market
the Stretta System, as an alternative to anti-reflux surgery, primarily to high volume general surgeons and gastroenterologists. In the United States, we estimate that there are approximately 4,500 general surgeons and 7,000 gastroenterologists who
actively perform endoscopy. We market the Secca System primarily to colon and rectal surgeons and to those general surgeons who perform colorectal surgery. We estimate that there are approximately 1,200 colon and rectal surgeons and up to 3,000
general surgeons that routinely perform colorectal surgery in the United States.



Our Stretta System has also received European, Australian and Canadian regulatory approval, and our Secca System has also received regulatory approval in Europe. We incorporated a subsidiary company in Belgium in November 2000 to manage
distribution of our products in Europe, the Middle East and Africa. We have entered into international distribution agreements in the following countries presented in alphabetical order, all of which cover the sale of both Stretta and Secca
products: Austria, Belgium, Brazil, China (PRC), China (Republic of), China (Hong Kong), Costa Rica, Denmark, Egypt, Finland, France, Germany, India, Indonesia, Ireland, Israel, Italy, Malaysia, The Netherlands, Norway, Philippines, Portugal,
Singapore, South Africa, South Korea, Spain, Sweden, Switzerland, Thailand, Turkey, United Arab Emirates, United Kingdom, Viet Nam, Some agreements cover more than one country. From time to time national distributors are replaced or terminated and
there may be times when we may have no representation in one or more of the above countries. Regulatory controls in certain countries prevent sales being made until the distributor completes the approval process. We are organized into a single
reportable segment consisting of the development, manufacture, and marketing of proprietary products for the treatment of gastrointestinal disorders. We use one measurement of profitability and do not disaggregate our business for internal
reporting.



The American Medical Association issued a Category I CPT code for
the Stretta procedure that became effective January 1, 2005, which will make it easier for physicians to code for the procedure. CPT codes are used to specify the physician component of the procedure cost.



RESULTS OF OPERATIONS



Periods of three and six months ended June 30, 2005 and 2004.



Revenues



Our revenues are comprised of sales of our Stretta and Secca generators and disposable devices. Revenues for the quarter ended June 30, 2005 were $1,152,000, compared to
$931,000 for the same quarter in 2004. The increase compared to 2004 was due primarily to an increase in sales of our Secca System products of $401,000, partially offset by a decline in sales of our Stretta System products of $166,000. Stretta
System products accounted for $593,000, or 52%, and Secca System products accounted for $544,000, or 48%, of the quarters revenues. In the second quarter of 2004, Stretta System products accounted for $759,000, or 84%, and Secca System



11



---

##### Table of Contents

products were $143,000, or 16%, of the quarters revenues. The Stretta Control Module and Catheter accounted for $187,000, or 32%, and $372,000, or 63%,
respectively, of the Stretta System product sales for the quarter ended June 30, 2005, compared to $361,000, or 48%, and $367,000, or 48%, respectively, for the same period in 2004. The Secca Control Module and Handpieces accounted for $194,000, or
36%, and $324,000, or 59%, respectively, of the Secca System product sales for the quarter ended June 30, 2005, compared to $37,000, or 26%, and $103,000, or 72%, respectively, for the same period in 2004. International sales accounted for $146,000
in the quarter ended June 30, 2005, compared to $21,000 in the same quarter of 2004.



Revenues for the six months ended June 30, 2005 were $2,009,000, compared to $1,837,000 for the same period in 2004. The increase compared to 2004 was due primarily to increased sales of Secca system products of $711,000, partially offset
by a decline in Stretta System products of $537,000. Stretta System products accounted for $1,061,000, or 54%, and Secca System products $908,000, or 46% of the revenues for the six months ended June 30, 2005, as compared to $1,598,000, or 89% and
$197,000, or 11%, respectively, for the same period in 2004. The Stretta Control Module and Catheter accounted for $290,000, or 27%, and $713,000, or 67%, respectively, of the Stretta System product sales for the six months ended June 30, 2005,
compared to $716,000, or 45%, and $812,000, or 51%, respectively, for the same period in 2004. The Secca Control Module and Handpieces accounted for $286,000, or 31%, and $584,000, or 64%, respectively, of the Secca System product sales for the six
months ended June 30, 2005, compared to $37,000, or 19%, and $157,000, or 79%, respectively, for the same period in 2004. International sales accounted for $281,000 in the six month ended June 30, 2005, compared to $30,000 in the same period of
2004.



Cost of goods sold



Our costs of goods sold represent the cost of producing generators and disposable devices.
Cost of goods sold was $1,013,000 or 88.9% of product sales revenue in the quarter ended June 30, 2005, compared to $1,110,000 or 123% of product sales revenue for the same period in 2004. For the six months ended June 30, 2005, cost of goods sold
was $1,995,000 or 100.4% of product sales revenue compared to $2,132,000 or 118.8% of product sales revenue for the same period in 2004.



Gross income (loss)



Gross income for the three months ended June 30, 2005 was $139,000 or 12% of sales compared to the gross loss of $179,000 or 19% of sales for the same period in 2004. For
the six months ended June 30, 2005, gross margin was $14,000 or 1% of sales compared to the gross loss of $295,000 or 16% of sales for the same period in 2004.



Research and development expenses



Research and development expenses consist primarily of personnel costs, professional services, patent application and maintenance costs, materials, supplies and
equipment. Research and development expenses were $301,000 for the three months ended June 30, 2005, a decrease of $132,000 or 30% over research and development expenses of $433,000 for the three months ended June 30, 2004. For the six months ended
June 30, 2005, research and development expenses were $594,000, a decrease of $336,000 or 36% over research and development expenses of $930,000 for the same period in 2004. The decrease in spending for the three and six months ended June 30, 2005
compared to the same periods of 2004 was due primarily to the reduced headcount in our research and development department as we implemented cost reduction measures in September 2004.



Clinical and regulatory expenses



Clinical and regulatory expenses consist primarily of expenses associated with the costs of clinical trials, clinical support personnel, the collection and analysis of
the results of these trials, and the costs of submission of the results to regulatory agencies. Clinical and regulatory expenses were $320,000 for the three months ended June 30, 2005, an increase of $38,000 or 13% over clinical and regulatory
expenses of $282,000 for the three months ended June 30, 2004. The increase of $38,000 in the second quarter 2005 compared to the second quarter 2004 was primarily attributable to other outside services. For the six months ended June 30, 2005,
clinical and regulatory expenses were $ 520,000, a decrease of $115,000 or 18% over clinical and regulatory expenses of $635,000 for the same period in 2004. Reduced clinical trial activity was the main reason of reduction of expenses.



Sales and marketing expenses



Sales and marketing expenses consist of personnel related costs, advertising, public
relations and attendance at selected medical conferences. Sales and marketing expenses for the three months ended June 30, 2005 were $2,509,000, an increase of $500,000 or 25% over sales and marketing expenses of $2,009,000 for the three months
ended June 30, 2004. The 14.2% of the increase or $285,000 of expense was driven by spending on new marketing programs and the remaining 10.7% of the increase or $215,000 was primarily attributable to trade shows and medical conferences. For the six
months ended June 30, 2005, sales and marketing expenses were $4,294,000, an increase of $216,000 or 5% over sales and marketing expenses of $4,078,000 for the same period in 2004.



12



---

##### Table of Contents

General and administrative expenses



General and administrative expenses consist primarily of the cost of corporate operations and personnel, legal, accounting and other general
operating expenses of our company. General and administrative expenses for the three months ended June 30, 2005 were $929,000, a decrease of $99,000 or 10% over general and administrative expenses of $1,028,000 for the three months ended June 30,
2004. For the six months ended June 30, 2005, general and administrative expenses were $1,868,000, a decrease of $145,000 or 7% over general and administrative expenses of $2,013,000 for the same period in 2004. This decrease in general and
administrative expenses for the three and six months ended June 30, 2005 compared to the same periods of 2004 was primarily due to decreased legal and professional fees.



Interest Income, net



During the quarter ended June 30, 2005, compared to the quarter ended June 30, 2004, net interest income decreased by $10,000. For the six months ended June 30, 2005,
compared to the same period in 2004, net interest income decreased by $32,000, due to a decrease in six month total average cash and investment balance of approximately $4 million, partially offset by an increase in investment yields to
approximately 3.2% from 1.25%. Interest expense was not material for any period presented.



Decrease in warrant obligation



Our sale of 18,445,078 newly issued shares on April 8 and June 3, 2005 included warrants to purchase an additional 2,481,298 and 6,741,241 respectively, shares of common stock to investors and warrants to purchase 553,352 shares of common
stock to our placement agent. Similar to our February 2004 warrants, these warrants provide for cash redemption by the holders upon the occurrence of certain events outside our control. As a result, the aggregate fair value of the warrants of $1.4
and $3.3 million, respectively, determined using the Black-Scholes model, was recorded as a liability on the issuance dates with subsequent changes to the fair value of the warrants being recorded as a non-operating item through the statement of
operations.



The following table shows the changes to the fair value of the
warrant obligations recorded as a non-operating (income) expense through the statement of operations for the three and six months ended June 30, 2005 and 2004:



|                    |  |                                     |      |   |                                   |   |      |      |  |   |      |   |  |   |        |  
|------------------- |  | ----------------------------------- | ---- | - | --------------------------------- | - | ---- | ---- |  | - | ---- | - |  | - | ------ | -
|                    |  | For the Three Months Ended June 30, |      |   | For the Six Months Ended June 30, |  
|Warrant issue dates |  | 2005                                |      |   | 2004                              |   |      | 2005 |  |   | 2004 |  
|June 3, 2005        |  | $                                   | 96   |   |                                   | $ |     |      |  | $ | 96   |   |  | $ |       |  
|April 8, 2005       |  |                                     | (189 | ) |                                   |   |     |      |  |   | (189 | ) |  |   |       |  
|February 6, 2004    |  |                                     | (60  | ) |                                   |   | (679 | )    |  |   | (398 | ) |  |   | (1,122 | )
|                    |  |                                     |      |   |                                   |   |      |      |  |   |      |   |  |   |        |  
|                    |  | $                                   | (153 | ) |                                   | $ | (679 | )    |  | $ | (491 | ) |  | $ | (1,122 | )
|                    |  |                                     |      |   |                                   |   |      |      |  |   |      |   |  |   |        |  



LIQUIDITY AND CAPITAL RESOURCES



We have been financing our operations primarily through our cash and cash
equivalents, revenues, marketable securities, and financing activities. We have incurred net losses since inception and expect to continue to do so for the next several years.



As of June 30, 2005, we had cash and cash equivalents on hand of $9.9 million and working capital of $10.6 million. We intend to finance our
operations primarily through cash and cash equivalents, marketable securities, future financing and future revenues. Based on current expectations of sales and operating costs, existing capital resources will not enable us to maintain current and
planned operations beyond the second quarter of 2006; however, if we do not receive certain expected product sales, our cash balance may not sustain planned operations beyond the end of the first quarter of 2006. We are pursuing a number of
alternatives to maximize stockholder value, including strategic transactions, collaborative partnerships and the licensing or sale of certain of our intellectual property. Licensing or collaborative arrangements, if necessary to raise additional
funds, may require us to relinquish rights to certain or all of our products or technologies. If these efforts are not successful, we will need to raise additional capital before the end of first quarter 2006 in order to continue operations. Any
additional financing may not be available in amounts or on terms acceptable to us, if at all. These issues raise substantial doubt about our ability to continue as a going concern.



13



---

##### Table of Contents

Net cash used in operating activities during the six months ended June 30, 2005 was $7.4 million, resulting primarily
from the net loss for the period of $6.7 million, increased by the $0.5 million non-cash gain resulting from the decrease in warrant liability, and increases in accounts receivable, prepaid and other current assets and inventories offset by net
decrease in accrued liabilities. For the six months ended June 30, 2004, net cash used in operating activities was $8.8 million, resulting primarily from the net loss for the period of $6.8 million, increased by the $1.1 million non-cash gain
resulting from the decrease in warrant liability, $1.25 million payment to settle legal liability reserve and increases in prepaid and other current assets, inventories and accounts payable partially offset by net decrease in accounts receivable and
accrued liabilities.



For the six months ended June 30, 2005, net cash provided
by investing activities was $3.3 million consisting primarily of net proceeds from net maturities of marketable securities used to fund operations. As of June 30, 2005, we had no material commitments for capital expenditures. For the six months
ended June 30, 2004, net cash used in investing activities was $7.5 million, which consisted primarily of net purchases of marketable securities, as we invested the cash received from our private placement financings in February 2004, partially
offset by $0.4 million of property and equipment acquisitions.



Cash provided
by financing activities was $11.5 million in the six months ended June 30, 2005, related to the private placement of common stock and common stock warrants to a group of institutional investors in the net amount of $11.0 million, in addition to $0.1
million from exercise of stock options and the Employee Stock Purchase Plan, and net cash provided by financing of business insurance in the amount of $0.4 million. For the same period in 2004, cash provided by financing activities was $13.3
million, related to the private placement of common stock and warrants to a group of institutional investors in the net amount of $12.7 million, in addition to $0.2 million from exercise of stock options and the Employee Stock Purchase Plan, and net
cash provided by financing of business insurance in the amount of $0.4 million.



Contractual Obligations



The following table sets forth our
contractual obligations at June 30, 2005 and the years in which such obligations are expected to be settled.



|                                 |  |      |     |      |   |      |  |       |    |  |   |      
|-------------------------------- |  | ---- | --- | ---- | - | ---- |  | ----- | -- |  | - | -----
|                                 |  | 2005 |     | 2006 |   | 2007 |  | Total
|Future minimum lease commitments |  | $    | 199 |      | $ | 338  |  | $     | 13 |  | $ | 550  
|Inventory purchase commitments   |  |      | 694 |      |   |     |  |       |   |  |   | 694  
|                                 |  |      |     |      |   |      |  |       |    |  |   |      
|                                 |  | $    | 893 |      | $ | 338  |  | $     | 13 |  | $ | 1,244
|                                 |  |      |     |      |   |      |  |       |    |  |   |      



In August 2002, we announced that our
Board of Directors had authorized a stock repurchase program permitting the purchase of up to 1,000,000 shares of our Common Stock in open market transactions at prices deemed appropriate by management, and administered pursuant to Rule 10b-18 of
the Securities Exchange Act of 1934. Shares have not been repurchased under this plan since 2002.



Recent Accounting Pronouncements



In
November 2004, the FASB issued SFAS No. 151, Inventory Costs. SFAS 151 amends the guidance in ARB No. 43, Chapter 4, Inventory Pricing, to clarify the accounting for abnormal amounts of idle facility expense, freight, handling costs and
spoilage. This statement requires that these items be expensed as incurred and not included in overhead. In addition, SFAS 151 requires that allocation of fixed production overhead to conversion costs should be based on normal capacity of the
production facilities. This Statement is effective for inventory costs incurred during fiscal years beginning after June 15, 2005. The adoption of SFAS No. 151 is not expected to have a material impact on our financial position and results of
operations.



In December 2004, the FASB issued Statement No. 123(R) (SFAS
123(R)), Share-Based Payment. This statement replaces Statement of Financial Accounting Standards No. 123 (SFAS 123), Accounting for Stock-Based Compensation, and supersedes APB Opinion No. 25,
Accounting for Stock Issued to Employees. SFAS 123(R) will require compensation costs related to share-based payment transactions to be recognized in the financial statements (with limited exceptions). The amount of compensation cost
will be measured based on the grant-date fair value of the equity or liability instruments issued. Compensation cost will be recognized over the period that an employee provides service in exchange for the award. This statement is effective as of
the beginning of the annual reporting period that begins after June 15, 2005. We are currently in the process of evaluating the impact from this standard on our results of operations and financial position.



In May 2005, the FASB issued SFAS No. 154, Accounting Changes and Error Corrections
(SFAS 154). This statement, which replaces APB Opinion No. 20, Accounting Changes, and FASB Statement No. 3, Reporting Accounting Changes in Interim Financial Statements, requires that a voluntary change in accounting principle be
applied retrospectively to all prior period financial statements



14



---

##### Table of Contents

presented, unless it is impracticable to do so. SFAS 154 also provides that a change in method of depreciating or amortizing a long-lived non-financial asset
be accounted for as a change in estimate effected by a change in accounting principle, and also provides that correction of errors in previously issued financial statements should be termed a restatement. SFAS 154 is effective for fiscal
years beginning December 15, 2005. We anticipate that the adoption of SFAS 154 will not have a material impact on our financial statements.



Factors That May Affect Future Results



Within the next year, we may have to raise additional funds to continue operations as currently conducted, or sell the Company. The terms of either transaction may not
be favorable to our stockholders.



We believe that unless revenues
increase and operating costs are controlled, our existing capital resources will not enable us to maintain current and planned operations beyond the second quarter of 2006. We may have to raise additional funds through the issuance of equity or debt
securities, or a combination thereof, in the public or private markets in order to continue operations, or sell the company. Additional financing and merger opportunities may not be available, or if available, may not be on favorable terms. The
availability of financing or merger opportunities will depend, in part, on market conditions, which have been depressed as of late. Any future equity financing could result in substantial dilution to our stockholders. If we raise additional funds by
issuing debt, we may be subject to limitations on our operations, through debt covenants or other restrictions. If adequate and acceptable financing is not available, we may have to delay development or commercialization of certain of our products
or license to third parties the rights to commercialize certain of our products or technologies that we would otherwise seek to commercialize. We may also reduce our marketing, customer support or other resources devoted to our products. Any of
these options could reduce our sales growth and result in continued net losses.



We may never achieve or maintain significant revenues or profitability.



We have incurred losses every year since we began operations. In particular, we incurred net losses of $15.3 million in 2004, $15.6 million in 2003, and $15.4 million in 2002 and $6.7 million for the six months ended
June 30, 2005. As of June 30, 2005, we had an accumulated deficit of approximately $101.3 million. Our revenues are, and will be, derived from the sale of radiofrequency generators and our disposable devices, such as the Stretta Catheter and Secca
Handpiece. We have generated limited revenues, and it is possible that we will never generate significant revenues from product sales. Even if we do achieve significant revenues from our product sales, we expect to incur significant net losses over
the next several years and these losses may increase. It is possible that we will never achieve profitable operations.



If health care providers are not adequately reimbursed for the procedures which use our products, or for the products themselves, we may never achieve significant
revenues.



Our physician customers continue to encounter difficulties in
readily obtaining adequate reimbursement for the Stretta procedure on a case-by-case basis, and this continues to impact our ability to market and sell the Stretta System.



While the American Medical Association has issued a Level I CPT code for the Stretta procedure effective January 1, 2005, there is no
assurance that the established level of coverage will encourage physicians to perform the Stretta procedure or that local Medicare or private payers will choose to pay for this procedure. We have in the past received unfavorable Medicare coverage
determinations. Physicians, hospitals and other health care providers are unlikely to purchase our products if they are not adequately reimbursed for the Stretta procedure or the products. Some payers may refuse adequate reimbursement even though
significant peer-reviewed data has been published. If users of our products cannot obtain sufficient reimbursement from health care payers for the Stretta or Secca procedures or the Stretta or Secca Systems disposables, then it is unlikely
that our products will ever achieve increased market acceptance.



Reimbursement from third-party health care payers is uncertain due to factors beyond our control and changes in third-party health care payers policies could adversely affect our sales growth.



Even if third-party payers provide adequate reimbursement for our procedures or products,
adverse changes in third-party payers policies toward reimbursement could preclude market acceptance for our products and have a material adverse effect on our sales and revenue growth. We are unable to predict what changes will be made in the
reimbursement methods used by third-party health care payers.



15



---

##### Table of Contents

For example, some health care payers are moving toward a managed care system in which providers contract to provide
comprehensive health care for a fixed cost per person. We cannot assure you that in a prospective payment system, which is used in many managed care systems, the cost of our products will be incorporated into the overall payment for the procedure or
that there will be adequate reimbursement for our products separate from reimbursement for the procedure.



Internationally, market acceptance of our products is dependent upon the availability of adequate reimbursement within prevailing health care payment systems. Reimbursement and health care payment systems in
international markets vary significantly by country and include both government-sponsored health care and private insurance. Although we are seeking international reimbursement approvals, we cannot assure you that any such approvals will be obtained
in a timely manner or at all. If foreign third-party payers do not adequately reimburse providers for the Stretta procedure and the products used with it, then our sales and revenue growth may be limited.



We may be delisted from the Nasdaq SmallCap Market if we fail to timely file our periodic
reports. This may adversely affect trading in our stock and our ability to raise capital.



Due to our inability to timely file our Form 10-Q for the quarter ended June 30, 2004, we became subject to delisting from the Nasdaq SmallCap Market. Subsequent to an appeal proceeding, the Nasdaq Listing
Qualifications Panel determined to continue our listing on the Nasdaq SmallCap Market, conditioned upon the timely filing of all periodic reports with the Securities and Exchange Commission and Nasdaq for all reporting periods beginning with
September 30, 2004 and ending on September 30, 2005. Should we fail to make any filing in accordance with this condition, we will not be entitled to a new hearing with Nasdaq and our securities may be immediately delisted from the Nasdaq SmallCap
Market.



There are no assurances that we will timely make our filings in
accordance with the terms of Nasdaqs conditional continued listing determination. If we are delisted, trading in our common stock could be subject to the so-called penny stock rules that impose additional sales practice and market
making requirements on broker-dealers who sell and/or make a market in those securities. Consequently, removal from the Nasdaq SmallCap Market, if it were to occur, could affect the ability or willingness of broker-dealers to sell and/or make a
market on our common stock and the ability of purchasers of our common stock to sell their securities in the secondary market. These rules could further limit the market liquidity of our common stock and the ability of investors to sell our common
stock in the secondary market. If we are delisted from the Nasdaq SmallCap Market, our stock price is likely to decline significantly.



We are not in compliance with the minimum bid price requirement of the Nasdaq SmallCap Market. We may consequently be required to implement a reverse stock split in
the future. This may increase volatility in the trading of our stock.



We
have failed to comply with the minimum $1.00 per share bid price requirement for continued listing on the Nasdaq SmallCap Market. The Nasdaq staff has notified us that our stock might be subject to delisting from the Nasdaq SmallCap Market if we
fail to regain compliance with the minimum bid price requirement. In order to regain compliance, we must evidence a closing bid price of $1.00 per share on or before November 14, 2005 and a closing bid price of at least $1.00 per share for a minimum
of ten consecutive business days immediately thereafter. Our stockholders have authorized up to a 1-for-4 reverse stock split on our stock. While we have no immediate plans to implement a reverse stock split, we may be required to do so in the
future to remain listed on the Nasdaq SmallCap Market. Should we implement a reverse stock split, the number of our shares being traded will be reduced and volatility in the trading of our stock may increase. Further, there are no assurances that a
reverse stock split will ensure compliance with the minimum bid price requirement. There are also no assurances that our stock price after a reverse stock split will be above $1.00 per share for ten consecutive trading days to remedy the minimum bid
price deficiency.



If physicians do not adopt our products, we will not
achieve future sales growth.



To achieve increasing sales, our products
must continue to gain recognition and adoption by physicians who treat gastrointestinal disorders. Our products represent a significant departure from conventional treatment methods. We believe that physicians will not increase rates of adoption of
our systems unless they determine, based on published peer-reviewed journal articles, long-term clinical data and their professional experience, that our systems provide effective and attractive alternatives to conventional means of treatment. Some
physicians may be slow to adopt new products and treatment practices, partly because of perceived liability risks and uncertainty of third-party reimbursement. As procedural technique plays a significant role in achieving positive results from the
Stretta and Secca Procedures, improper use of either system may have unsatisfactory patient outcomes or cause adverse events, leading to physician dissatisfaction, negative publicity, or lawsuits. Additionally, some of our customers and potential
customers may find the time necessary to perform a Stretta procedure to be a limiting issue, as their endoscopy unit schedule is typically dominated by short diagnostic procedures. Future adverse events or recalls could also impact future acceptance
rates. If we cannot achieve increasing physician adoption rates of our products, we may never achieve significant revenues or profitability.



16



---

##### Table of Contents

Our internal controls may not be sufficient to ensure timely and reliable financial information.



In October 2004, we restated our financial results for the quarter ended March 31, 2004 to
reflect adjustments to our previously reported financial information. The restatements arose, in part, out of an internal investigation by the Audit Committee. As a result of the investigation, management and the Audit Committee determined that
certain sales employees had improperly offered rights of return and exchange in violation of our revenue recognition policy, and a manufacturers representative had not actually made sales that it had reported to the Company. As a result of
this investigation, we were also unable to timely file the Form 10-Q for the quarter ended June 30, 2004. In connection with the restatement of our financial results for the quarter ended March 31, 2004, our independent registered public accounting
firm identified material weaknesses in our internal controls and procedures.



Our Audit Committee, with the assistance of independent legal and accounting advisors, evaluated the effectiveness of our disclosure controls and procedures. As a result of this evaluation, our Board of Directors has directed management to
implement and management has implemented additional measures designed to ensure that information required to be disclosed in our periodic reports is recorded, processed, summarized and reported accurately. These measures include the adoption of a
Disclosure Committee Charter, the adoption of a written revenue recognition policy, further controls on shipment of products for revenue transactions, and additional training of our sales and marketing staff to minimize the risk of revenue
recognition errors. The effectiveness of our controls and procedures remain limited by a variety of factors including:



| |  | Faulty human judgment and simple errors, omissions or mistakes;
|- |  | ---------------------------------------------------------------



| |  | Fraudulent action of an individual or collusion of two or more people;
|- |  | ----------------------------------------------------------------------



| |  | Inappropriate management override of procedures; and
|- |  | ----------------------------------------------------



| |  | The possibility that our enhanced controls and procedures may still not be adequate to assure timely and accurate financial information.
|- |  | ----------------------------------------------------------------------------------------------------------------------------------------



If we fail to have effective internal control over financial reporting in place, we could be
unable to provide timely and accurate financial information and be subject to delisting from Nasdaq, and civil or criminal sanctions.



We face competition from more established GERD treatments and from competitors with greater resources, which will make it difficult for us to achieve significant
market penetration.



Companies that have well-established products,
reputations and resources dominate the market for the treatment of GERD. Our primary competitors are large medical device manufacturers such as Ethicon Endo Surgery and United States Surgical, manufacturers of instrumentation for anti-reflux
surgery, C.R. Bard, Wilson Cook and NDO Surgical, each of which manufactures an endoscopic sewing device for treating GERD, and Boston Scientific, which manufactures an injectable product for the treatment of GERD. Other competitive devices may be
developed.



Most of these competitors are larger companies that enjoy several
competitive advantages over us, which may include:



| |  |  | Existing anti-reflux surgical procedures and devices for the treatment of GERD;
| | - |  | -------------------------------------------------------------------------------



| |  |  | Established reputations within the surgical and gastroenterological community;
| | - |  | ------------------------------------------------------------------------------



| |  |  | Established distribution networks that permit these companies to introduce new products and have such products accepted by the physician community promptly;
| | - |  | ------------------------------------------------------------------------------------------------------------------------------------------------------------



| |  |  | Established relationships with health care providers and payers that can be used to facilitate reimbursement for new treatments; and
| | - |  | ------------------------------------------------------------------------------------------------------------------------------------



| |  |  | Greater resources for product development and sales and marketing.
| | - |  | ------------------------------------------------------------------



We do not feel that we compete with large pharmaceutical companies, such as AstraZeneca, Takeda Abbott Pharmaceutical, Wyeth Laboratories and Eisai, because candidate
patients for Stretta are intolerant to drug therapy or have failed, or only partially responded to, drug therapy. However, these companies have an established relationship with the gastroenterology community and generate over $12 billion in annual
U.S. revenues from the proton pump inhibitor drug class. We could be adversely affected if one or more pharmaceutical companies elects to market aggressively against our product, or if a new, more effective, pharmaceutical product is developed.



17



---

##### Table of Contents

We have limited sales and marketing resources, and failure to manage our sales force or to market and distribute our
products effectively will hurt our revenues.



We have limited sales and
marketing resources. As of June 30, 2005, we relied on 14 direct sales territories for the sale of our products in the United States. We also deploy an indirect sales channel of five manufacturers representative firms, which adds 11 salespeople
available to sell and market our products across the United States. The success of this sales channel will depend upon a number of factors, many of which are beyond our control, including the willingness of such distributors to prioritize the sale
of our products, and their effectiveness in such sales efforts.



There are
significant risks involved in building and managing our sales force and marketing our products, including our:



| |  |  | Inability to hire a sufficient number of qualified sales people with the skills and understanding to sell the Stretta and Secca Systems effectively;
| | - |  | ----------------------------------------------------------------------------------------------------------------------------------------------------



| |  |  | Failure to adequately train our sales force in the use and benefits of our products, making them less effective promoters; and
| | - |  | ------------------------------------------------------------------------------------------------------------------------------



| |  |  | Failure to accurately price our products as attractive alternatives to conventional treatments.
| | - |  | -----------------------------------------------------------------------------------------------



Our failure to adequately address these risks will harm our ability to sell our products.



Internationally, we rely on third-party distributors to sell our products, and we cannot
assure you that these distributors will commit the necessary resources to effectively market and sell our products.



Internationally, we rely on a network of distributors to sell our products and we will need to attract additional distributors to grow our business and expand the
territories into which we sell our products. Distributors may not commit the necessary resources to market and sell our products to the level of our expectations. If current or future distributors do not perform adequately, we may not realize
expected international revenue growth.



We depend on suppliers who provide
materials and components used in our products, and if we lose our relationship with any individual supplier, we may face regulatory requirements with regard to replacement suppliers that could delay the manufacture of our products.



Third-party suppliers provide materials and components used in our products, some of
which are the single or sole source for the components they provide. If any of our suppliers become unwilling or unable to supply us with our requirements, replacement or alternative sources might not be readily obtainable due to regulatory
requirements applicable to our manufacturing operations. Obtaining components from a new supplier may require a new or supplemental filing with applicable regulatory authorities and clearance or approval of the filing before we could resume product
sales. This process may take a substantial period of time, and we cannot assure you that we would be able to obtain the necessary regulatory clearance or approval. This could create supply disruptions that would reduce our product sales and revenue.



If we, or our suppliers, fail to comply with the FDA Quality System
Regulation, manufacturing operations could be delayed and our business could be harmed.



Our manufacturing processes are required to comply with the Quality System Regulation, or QSR, which covers the methods and documentation of the design, testing, production, control, quality assurance, labeling,
packaging and shipping of our products. The FDA enforces the QSR through inspections. Our first QSR inspection was in March 2001, and we were also inspected in July 2003. There were no significant findings from either inspection. If we fail any
future QSR inspections, our operations could be disrupted and our manufacturing delayed. Failure to take appropriate corrective action in response to a QSR inspection could force a shut-down of our manufacturing operations, a recall of our products,
and potentially a revocation of the FDA 510(k) clearance of our products, which would have a material adverse effect on our product sales, revenues, expected revenues and profitability. Furthermore, we cannot assure you that our key component
suppliers are, or will continue to be, in compliance with applicable regulatory requirements, will not encounter any manufacturing difficulties, or will be able to maintain compliance with regulatory requirements. Any such event could have a
material adverse effect on our available inventory and product sales.



Our
failure to obtain or maintain necessary FDA clearances or approvals could hurt our ability to commercially distribute and market our products in the United States.



Our products are medical devices and are therefore subject to extensive regulation in the United States and in foreign countries where we
intend to do business. Unless an exemption applies, each new Class II or III medical device that we wish to market in the United States must first receive either 510(k) clearance or premarket approval from the FDA. Either process can be lengthy and
expensive.



18



---

##### Table of Contents

The FDAs 510(k) clearance process usually takes from four to twelve months, but may take longer. The premarket application, or PMA, approval process is
much more costly, lengthy and uncertain. It generally takes from one to three years or even longer. Delays in obtaining regulatory clearance or approval will adversely affect our ability to generate revenues and profitability from new products. We
cannot assure you that the FDA will ever grant 510(k) clearance or premarket approval for any new product we propose to market. If the FDA withdraws or refuses to grant approvals, we will be unable to market such products in the United States.



If we market our products for uses that the FDA has not approved, we could
be subject to FDA enforcement action.



Our Stretta and Secca Systems are
cleared by the FDA, the Stretta System for the treatment of GERD and the Secca System for the treatment of bowel incontinence in patients who have failed more conservative therapies such as diet modification and biofeedback. FDA regulations prohibit
us from promoting or advertising either system, or any future cleared or approved devices, for uses not within the scope of our clearances or approvals. These determinations can be subjective, and the FDA may disagree with our promotional claims. If
the FDA requires us to revise our promotional claims or takes enforcement action against us based upon our labeling and promotional materials, our sales could be delayed, our profitability could be harmed and we could be required to pay significant
fines or penalties.



Modifications to our marketed devices may require new
510(k) clearances or PMA approvals or require us to cease marketing or recall the modified devices until such clearances are obtained.



Any modification to an FDA 510(k)-cleared device that could significantly affect its safety or effectiveness, or that would constitute a major change in its intended use,
requires a new FDA 510(k) clearance or, possibly, PMA approval. The FDA requires every manufacturer to make this determination in the first instance, but the FDA can review any such decision. We have modified aspects of our products, but we believe
that new 510(k) clearances are not required. We may modify future products after they have received clearance or approval, and, in appropriate circumstances, we may determine that new clearance or approval is unnecessary. Though we believe these
changes fall within the acceptable scope of changes allowed for Class II devices, we cannot assure you that the FDA would agree with any of our decisions not to seek new clearance or approval. If the FDA requires us to seek 510(k) clearance or PMA
approval for any modification to a previously cleared product, we also may be required to cease marketing or recall the modified device until we obtain such clearance or approval. Also, in such circumstances, we may be subject to significant
regulatory fines or penalties.



We face risks related to our international
operations, including the need to obtain necessary foreign regulatory approvals.



To date we have international distribution agreements for countries in Europe, Asia, Africa, and Central America. We have obtained regulatory clearance to market the Stretta System in the European Union, Australia and Canada and to market
the Secca System in the European Union. Marketing our products in additional countries may require regulatory approvals. We cannot assure you that we will be able to obtain or maintain such approvals. Furthermore, although contracts already signed
with international distributors specify payment in U.S. dollars, future international sales may be made in currencies other than the U.S. dollar. As a result, currency fluctuations may impact the demand for our products in countries where the U.S.
dollar has increased compared to the local currency. Engaging in international business involves the following additional risks:



| |  |  | Export restrictions, tariff and trade regulations, and foreign tax laws;
| | - |  | ------------------------------------------------------------------------



| |  |  | Customs duties, export quotas or other trade restrictions;
| | - |  | ----------------------------------------------------------



| |  |  | Economic or political instability;
| | - |  | ----------------------------------



| |  |  | Shipping delays; and
| | - |  | --------------------



| |  |  | Longer payment cycles.
| | - |  | ----------------------



In addition, contracts may be difficult to enforce and receivables difficult to collect through a foreign countrys legal system, and the protection of intellectual property in foreign countries may be more
difficult to enforce. Any of these factors could cause our international sales to decline, which would impact our expected sales and growth rates.



Product liability suits against us may result in expensive and time-consuming litigation, payment of substantial damages and an increase in our insurance rates.



The development, manufacture and sale of medical products involves a
significant risk of product liability claims. The use of any of our products may expose us to liability claims, which could divert managements attention from our core business, could be expensive to defend, and could result in substantial
damage awards against us. For example, we have been party to product liability lawsuits in which there were allegations that our products were defectively designed and that we were negligent in our manufacturing.



19



---

##### Table of Contents

We maintain product liability insurance at coverage levels we believe to be commercially acceptable, and we re-evaluate
annually whether we need to obtain additional product liability insurance. However there can be no assurance that product liability or other claims will not exceed such insurance coverage limits or that such insurance will continue to be available
on the same or substantially similar terms, or at all. Any product liabilities claims brought against us, with or without merit, could increase our product liability insurance rates or prevent us from securing any coverage in the future.



We have limited protection for our intellectual property. If our intellectual property
does not sufficiently protect our products, third parties will be able to compete against us more directly and more effectively.



We rely on patent, copyright, trade secret and trademark laws to protect our products, including our Stretta Catheter, our Secca Handpiece and our Curon Control Module,
from being duplicated by competitors. However, these laws afford only limited protection. Our patent applications and the notices of allowance we have received may not issue as patents or, if issued, may not issue in a form that will be advantageous
to us. Patents we have obtained and may obtain in the future may be challenged, invalidated or legally circumvented by third parties. We may not be able to prevent the unauthorized disclosure or use of our technical knowledge or other trade secrets
by consultants, vendors, former employees or current employees, despite the existence of nondisclosure and confidentiality agreements and other contractual restrictions. Furthermore, the laws of foreign countries may not protect our intellectual
property rights to the same extent as the laws of the United States. If our intellectual property rights do not adequately protect our commercial products, our competitors could develop new products or enhance existing products to compete more
directly and effectively with us and harm our product sales and market position.



Because, in the United States, patent applications are secret unless and until issued as patents, or corresponding applications are published in other countries, and because publication of discoveries in the scientific or patent literature
often lags behind actual discoveries, we cannot be certain that we were the first to file patent applications for such inventions. Litigation or regulatory proceedings, which could result in substantial cost and uncertainty, may also be necessary to
enforce patent or other intellectual property rights or to determine the scope and validity of other parties proprietary rights. There can be no assurance that we will have the financial resources to defend our patents from infringement or
claims of invalidity.



Because of our reliance on unique technology to
develop and manufacture innovative products, we depend on our ability to operate without infringing or misappropriating the proprietary rights of others.



There is a substantial amount of litigation over patent and other intellectual property rights in the medical device industry. Because we rely on unique technology to
develop and manufacture innovative products, we are especially sensitive to the risk of infringing intellectual property rights. While we attempt to ensure that our products do not infringe other parties patents and proprietary rights, our
competitors may assert that our products and the methods they employ may be covered by patents held by them or invented by them before they were invented by us. Although we may seek to obtain a license or other agreement under a third partys
intellectual property rights to bring an end to certain claims or actions asserted against us, we may not be able to obtain such an agreement on reasonable terms or at all. If we were not successful in obtaining a license or redesigning our
products, our product sales and profitability could suffer, and we could be subject to litigation and potentially substantial damage awards.



Also, one or more of our products may now be infringing inadvertently on existing patents. As the number of competitors in our markets grows, the possibility of a patent
infringement claim against us increases. Whether a product infringes a patent involves complex legal and factual issues, the determination of which is often uncertain. Infringement and other intellectual property claims, with or without merit, can
be expensive and time-consuming to litigate and divert managements attention from our core business. If we lose in this kind of litigation, a court could require us to pay substantial damages or grant royalties, and prohibit us from using
technologies essential to our products. This kind of litigation is expensive to all parties and consumes large amounts of managements time and attention. In addition, because patent applications can take many years to issue, there may be
applications now pending of which we are unaware and which may later result in issued patents that our products may infringe.



If we lose our rights to intellectual property that we have licensed we may be forced to develop new technology and we may not be able to develop that technology or
may experience delays in manufacturing as a result.



Our license with
Gyrus Group PLC, a public company incorporated and existing under the laws of England and Wales, allows us to manufacture and sell our products using their radiofrequency generator technology. In addition, the University of Kansas license allows us
to apply radiofrequency energy to tissue. To the extent these license interests become jeopardized through termination or material breach of the license agreements, our operations may be harmed. We may have to develop new technology or license other



20



---

##### Table of Contents

technology. We cannot provide any assurance that we will be able to develop such technology or that other technology will be available for license. Even if
such technology is available, we may experience delays in our manufacturing as we transition to a different technology.



If we are unable to attract and retain qualified personnel, we will be unable to expand our business.



We believe our future success will depend upon our ability to successfully manage our
employees, which includes attracting and retaining engineers and other highly skilled personnel. Our employees are at-will employees and are not subject to employment contracts. The loss of services of one or more key employees could materially
adversely affect our growth. In addition, our stock price is depressed and the results of our operations have been less successful than anticipated. This history of performance may make it difficult to attract and retain qualified personnel. Failure
to attract and retain personnel, particularly management and technical personnel, would materially harm our ability to grow our business rapidly and effectively.



Our directors, executive officers and principal stockholders have significant voting power and may take actions that may not be in the
best interests of our other stockholders.



Our officers, directors and
principal stockholders holding more than 5% of our common stock together control over 50% of our outstanding common stock. As a result, these stockholders, if they act together, will be able to control the management and affairs of our company and
all matters requiring stockholder approval, including the election of directors and approval of significant corporate transactions. This concentration of ownership may have the effect of delaying or preventing a change in control and might adversely
affect the market price of our common stock. This concentration of ownership may not be in the best interest of our other stockholders.



Our stockholder rights plan, certificate of incorporation, bylaws and Delaware law contain provisions that could discourage a takeover.



In November 2001, we adopted a stockholder rights plan. The purpose of the plan is to assure
fair value in the event of a future unsolicited business combination or similar transaction involving Curon. If an individual or entity accumulates 15% of our stock, or 20% in the case of certain existing stockholders, the rights become exercisable
for additional shares of our common stock or, if followed by a merger or other business combination where Curon does not survive, additional shares of the acquirers common stock. The intent of these rights is to force a potential acquirer to
negotiate with the Board to increase the consideration paid for our stock. The existence of this plan, however, may deter a potential acquirer, which could negatively impact shareholder value.



In addition, our basic corporate documents and Delaware law contain provisions that might
enable our management to resist a takeover. Any of the above provisions might discourage, delay or prevent a change in the control of our company or a change in our management. The existence of these provisions could adversely affect the voting
power of holders of common stock and limit the price that investors might be willing to pay in the future for shares of our common stock.



Item3. Quantitative and Qualitative Disclosures of Market Risk



We invest our excess cash primarily in U.S. government securities and marketable debt securities of financial institutions and corporations with strong credit ratings. These instruments have maturities of eighteen
months or less when acquired, with an average maturity date of at least six months. We do not utilize derivative financial instruments, derivative commodity instruments or other market risk sensitive instruments, positions or transactions in any
material fashion. Accordingly, we believe that while the instruments we hold are subject to changes in the financial standing of the issuer of such securities, we are not subject to any material risks arising from changes in interest rates, foreign
currency exchange rates, commodity prices, equity prices or other market changes that affect market risk sensitive instruments.



Item 4. Controls and Procedures



(a) Evaluation of disclosure controls and procedures.



We
maintain disclosure controls and procedures, as such term is defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934 (the Exchange Act), that are designed to ensure that information required to be
disclosed by us in reports that we file or submit under the Exchange Act is recorded, processed, summarized, and reported within the time periods specified in Securities and Exchange Commission rules and forms, and that such information is
accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure. In designing and evaluating our disclosure controls and
procedures, management recognized that disclosure controls and procedures, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the



21



---

##### Table of Contents

objectives of the disclosure controls and procedures are met. Additionally, in designing disclosure controls and procedures, our management necessarily was
required to apply its judgment in evaluating the cost-benefit relationship of possible disclosure controls and procedures. The design of any disclosure controls and procedures also is based in part upon certain assumptions about the likelihood of
future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions.



Our management, with the participation of our Chief Executive Officer and Chief Financial Officer, has evaluated the effectiveness of the design and operation of our
disclosure controls and procedures as of the end of the quarter covered by this Quarterly Report on Form 10-Q. Based on that evaluation, the Chief Executive Officer and Chief Financial Officer have concluded that, as of such date, our disclosure
controls and procedures were effective.



(b) Changes in
internal control over financial reporting.



There were no changes in our
internal control over financial reporting during the quarter ended June 30, 2005, that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.



PART II OTHER INFORMATION



Item 1. Legal Proceedings



In April 2003, a civil
action was filed against us in United States District Court for the Northern District of California by Federal Insurance Corporation, our insurance carrier, for rescission, reformation, and restitution in connection with the our liability insurance
policy. This policy covers, among other things, product liability claims made against us by people treated with our product. In October 2004, the Plaintiffs summary judgment motion was granted. We decided not to appeal the result of the
summary judgment and have agreed to settlement terms with Federal Insurance Corporation. The settlement as agreed will end any further liability in this matter and will result in a partial recovery of premiums paid. We expect both parties to sign
the settlement documents in the third quarter of 2005.



ITEM 2. Unregistered Sale of Equity Securities and Use of Proceeds



Previously furnished



ITEM 3. Defaults Upon Senior Securities



None



ITEM 4. Submission of Matters to a Vote of Security Holders



We distributed our Definitive Proxy Statement, Proxy and Annual Report to Stockholders on or about May 4, 2005 to each stockholder of record as of April 22, 2005, for our Annual Meeting of Stockholders held on May 31,
2005. At our Annual Meeting, the stockholders were asked to consider five proposals.



The first proposal involved the election of two Class II directors. The nominating committee of the Board of Directors selected two nominees, who ran unopposed. All the nominees were then serving as our directors. The nominees of the Board,
and the voting results with respect thereto, were:



|                       |  |            |  |          
|---------------------- |  | ---------- |  | ---------
|Name                   |  | Votes For  |  | Withheld 
|Robert F. Kuhling, Jr. |  | 25,486,427 |  | 1,389,070
|Larry J. Strauss       |  | 25,486,427 |  | 1,389,070



The second proposal was the
ratification of our independent registered public accounting firm PricewaterhouseCoopers LLP, for the fiscal year ending December 31, 2005. The number of shares cast for, against, and abstentions were 25,459,927, 1,410,370, and 5,200, respectively.
The affirmative vote of a majority of the votes cast on the proposal at the Annual Meeting was required for approval of this proposal. The percentage of shares voted in favor of this proposal was 85% of the shares of Common Stock outstanding.
Therefore, the stockholders approved proposal two.



22



---

##### Table of Contents

The third proposal was an amendment to our Certificate of Incorporation to increase the number of authorized shares of
our Common Stock by 50,000,000 shares, from 50,000,000 to 100,000,000. The number of shares cast for, against and abstentions were 24,796,927, 2,050,085, and 28,545, respectively. The affirmative vote of a majority of the shares of Common Stock
outstanding as of the record date was required for approval of this proposal. The percentage of shares voted in favor of this proposal was 83% of the shares of Common Stock outstanding. Therefore, the stockholders approved proposal three.



The fourth proposal was the approval of the issuance of securities in
connection with a financing transaction. The number of shares cast for, against, and abstentions were 13,481,386, 5,006,495, and 33,245, respectively. The affirmative vote of a majority of the votes cast on the proposal at the Annual Meeting was
required for approval of this proposal. The percentage of shares voted in favor of this proposal was 73% of the shares of Common Stock that voted on the proposal. Therefore, the stockholders approved proposal four.



The fifth and final proposal was the authorization to effect up to a 1-for-4 reverse stock
split. The number of shares cast for, against, and abstentions were 21,612,014, 5,123,690, and 139,703, respectively. A majority of the votes cast on the proposal at the Annual Meeting was required for approval of this proposal. The percentage of
shares voted in favor of this proposal was 73% of the votes cast on the proposal. Therefore, the stockholders approved proposal five.



Item 5. Other Information



None



Item 6. Exhibits



(a) Exhibits.



|            |  |                                                                                                                                                  
|----------- |  | -------------------------------------------------------------------------------------------------------------------------------------------------
|Exhibit No. |  | Description                                                                                                                                      
|31.1        |  | Chief Executive Officers Certification Pursuant to 15 U.S.C. Section 7241, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
|            | 
|31.2        |  | Chief Financial Officers Certification Pursuant to 15 U.S.C. Section 7241, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
|            | 
|32.1        |  | Certificate of Chief Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. 
|            | 
|32.2        |  | Certificate of Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. 



23



---

##### Table of Contents

CURON MEDICAL, INC.



SIGNATURES



Pursuant to the requirements of the Securities Exchange
Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.



|                     |  |                     |  |                                                                                                                                  
|-------------------- |  | ------------------- |  | ---------------------------------------------------------------------------------------------------------------------------------
|                     |  | CURON MEDICAL, INC.
|                     |  | (Registrant)       
|                     |  |                    
|Date: August 2, 2005 |  | By:                 |  | /s/ LARRY C. HEATON II                                                                                                           
|                     |  |                     |  | Larry C. Heaton II President and Chief Executive Officer (Principal Executive Officer)                                           
|                     |  |                    
|                     |  | By:                 |  | /s/ ALISTAIR F. MCLAREN                                                                                                          
|                     |  |                     |  | Alistair F. McLaren Vice President of Finance Chief Financial Officer and Chief Information Officer (Principal
Financial Officer)



24